Genomic polymorphisms in sepsis

Critical Care Medicine

Volumn 32, Issue 2, 2004, Pages 569-579

  Lin, Mark T ^a   Albertson, Timothy E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Genetics; Immunity; Polymorphism; Sepsis

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; MANNOSE BINDING LECTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL CELL WALL; CLINICAL TRIAL; CORRELATION ANALYSIS; DATA ANALYSIS; DNA MICROARRAY; GENETIC POLYMORPHISM; HUMAN; IMMUNITY; INFECTION; MODEL; MORTALITY; NONHUMAN; PATHOGENESIS; POPULATION; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; SURVIVAL;

HUMANS; IMMUNITY, NATURAL; PEPTIDYL-DIPEPTIDASE A; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; SEPSIS;

EID: 1242320032     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000110878.49476.42     Document Type: Review

References (129)

1. Abraham E, Matthay MA, Dinarello CA, et al: Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: Time for a reevaluation. Crit Care Med 2000; 28: 232-235
2. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554
3. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
4. Angus DC, Wax RS: Epidemiology of sepsis: An update. Crit Care Med 2001; 29(7 Suppl):S109-S116
5. Milberg JA, Davis DR, Steinberg KP, et al: Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993. JAMA 1995; 273:306-309
6. Rangel-Frausto MS, Pittet D, Costigan M, et al: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273:117-123
7. The Acute Respiratory Distress Syndrome Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342:1301-1308
8. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
9. Rivers E, Nguyen B, Havstad S, et al: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377
10. Vincent JL, Sun Q, Dubois MJ: Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2002; 34:1084-1093
11. Sorensen TI, Nielsen GG, Andersen PK, et al: Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988; 318:727-732
12. Cooke GS, Hill AV: Genetics of susceptibility to human infectious disease. Nat Rev Genet 2001; 2:967-977
13. Cardon LR, Bell JI: Association study designs for complex diseases. Nat Rev Genet 2001; 2:91-99
14. Brookes AJ: The essence of SNPs. Gene 1999; 234:177-186
15. Risch NJ: Searching for genetic determinants in the new millennium. Nature 2000; 405:847-856
16. Silverman EK, Palmer LJ: Case-control association studies for the genetics of complex respiratory diseases. Am J Respir Cell Mol Biol 2000; 22:645-648
17. Sachidanandam R, Weissman D, Schmidt SC, et al: A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001; 409:928-933
18. Weiss J, Muello K, Victor M, et al: The role of lipopolysaccharides in the action of the bactericidal/permeability-increasing neutrophil protein on the bacterial envelope. J Immunol 1984; 132:3109-3115
19. Schumann RR, Leong SR, Flaggs GW, et al: Structure and function of lipopolysaccharide binding protein. Science 1990; 249: 1429-1431
20. Ulevitch RJ, Tobias PS: Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 1995; 13: 437-457
21. Elsbach P, Weiss J: Role of the bactericidal/permeability-increasing protein in host defence. Curr Opin Immunol 1998; 10:45-49
22. Tobias PS, Soldau K, Iovine NM, et al: Lipopolysaccharide (LPS)-binding proteins BPI and LBP form different types of complexes with LPS. J Biol Chem 1997; 272: 18682-18685
23. Wright SD, Ramos RA, Tobias PS, et al: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249:1431-1433
24. Ziegler-Heitbrock HW, Ulevitch RJ: CD14: Cell surface receptor and differentiation marker. Immunol Today 1993; 14:121-125
25. Dziarski R, Tapping RI, Tobias PS: Binding of bacterial peptidoglycan to CD14. J Biol Chem 1998; 273:8680-8690
26. Fan X, Stelter F, Menzel R, et al: Structures in Bacillus subtilis are recognized by CD14 in a lipopolysaccharide binding protein-dependent reaction. Infect Immun 1999; 67:2964-2968
27. Pugin J, Schurer-Maly CC, Leturcq D, et al: Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci U S A 1993; 90:2744-2748
28. Jack RS, Fan X, Bernheiden M, et al: Lipopolysaccharide-binding protein is required to combat a murine Gram-negative bacterial infection. Nature 1997; 389: 742-745
29. Ferrero E, Jiao D, Tsuberi BZ, et al: Transgenic mice expressing human CD14 are hypersensitive to lipopolysaccharide. Proc Natl Acad Sci U S A 1993; 90:2380-2384
30. Haziot A, Ferrero E, Lin XY, et al: CD14-deficient mice are exquisitely insensitive to the effects of LPS. Prog Clin Biol Res 1995; 392:349-351
31. Burgmann H, Winkler S, Locker GJ, et al: Increased serum concentration of soluble CD14 is a prognostic marker in Gram-positive sepsis. Clin Immunol Immunopathol 1996; 80:307-310
32. Landmann R, Zimmerli W, Sansano S, et al: Increased circulating soluble CD14 is associated with high mortality in Gram-negative septic shock. J Infect Dis 1995; 171:639-644
33. Hubacek JA, Stuber F, Frohlich D, et al: Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: Gender-specific genetic predisposition to sepsis. Crit Care Med 2001; 29:557-561
34. Hubacek JA, Rothe G, Pit'ha J, et al: C(-260)->T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation 1999; 99:3218-3220
35. Baldini M, Lohman IC, Halonen M, et al: A Polymorphism* in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999; 20:976-983
36. Hubacek JA, Stuber F, Frohlich D, et al: The common functional C(-159)T polymorphism within the promoter region of the lipopolysaccharide receptor CD14 is not associated with sepsis development or mortality. Genes Immun 2000; 1:405-407
37. Gibot S, Cariou A, Drouet L, et al: Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate. Crit Care Med 2002; 30:969-973
38. B. Beutler: Toll-like receptors: How they work and what they do. Curr Opin Hematol 2002; 9:2-10
39. Takeuchi O, Hoshino K, Kawai T, et al: Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 1999; 11:443-451
40. Hoshino K, Takeuchi O, Kawai T, et al: Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TLR4 as the Lps gene product. J Immunol 1999; 162: 3749-3752
41. Poltorak A, He X, Smirnova I, et al: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 1998; 282:2085-2088
42. Arbour NC, Lorenz E, Schutte BC, et al: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25:187-191
43. Lorenz E, Mira JP, Frees KL, et al: Relevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock. Arch Intern Med 2002; 162:1028-1032
44. Read RC, Pullin J, Gregory S, et al: A functional polymorphism of toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease. J Infect Dis 2001; 184:640-642
45. Aliprantis AO, Yang RB, Mark MR, et al: Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 1999; 285:736-739
46. Brightbill HD, Libraty DH, Krutzik SR, et al: Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999; 285:732-736
47. Lorenz E, Mira JP, Cornish JL, et al: A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2000; 68:6398-6401
48. Figueroa JE, Densen P: Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991; 4:359-395
49. Turner MW: Mannose-binding lectin (MBL) in health and disease. Immunobiology 1998; 199:327-339
50. Summerfield JA, Ryder S, Sumiya M, et al: Mannose binding protein gene mutations associated with unusual and severe infections in adults. Lancet 1995; 345:886-889
51. Tabona P, Mellor A, Summerfield JA: Mannose binding protein is involved in first-line host defence: Evidence from transgenic mice. Immunology 1995; 85:153-159
52. Turner MW: Mannose-binding lectin: The pluripotent molecule of the innate immune system. Immunol Today 1996; 17:532-540
53. Madsen HO, Garred P, Thiel S, et al: Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995; 155: 3013-3020
54. Neth O, Hann I, Turner MW, et al: Deficiency of mannose-binding lectin and burden of infection in children with malignancy: A prospective study. Lancet 2001; 358:614-618
55. Peterslund NA, Koch C, Jensenius JC, et al: Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet 2001; 358:637-638
56. Hibberd ML, Sumiya M, Summerfield JA, et al: Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet 1999; 353: 1049-1053
57. van der Pol W, van de Winkel JG: IgG receptor polymorphisms: Risk factors for disease. Immunogenetics 1998; 48:222-232
58. Sanders LA, Feldman RG, Voorhorst-Ogink MM, et al: Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils. Infect Immun 1995; 63:73-81
59. Bredius RG, Fijen CA, De Haas M, et al: Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes. Immunology 1994; 83:624-630
60. Koene HR, Kleijer M, Algra J, et al: Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90:1109-1114
61. Salmon JE, Edberg JC, Brogle NL, et al: Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function. J Clin Invest 1992; 89:1274-1281
62. Platonov AE, Shipulin GA, Vershinina IV, et al: Association of human Fc gamma RIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease. Clin Infect Dis 1998; 27:746-750
63. van der Pol WL, Huizinga TW, Vidarsson G, et al: Relevance of Fcgamma receptor and interleukin-10 polymorphisms for meningococcal disease. J Infect Dis 2001; 184: 1548-1555
64. Dinarello CA: Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 1997; 112(6 Suppl):321S-329S
65. Wheeler AP, Bernard GR: Treating patients with severe sepsis. N Engl J Med 1999; 340: 207-214
66. Knight J: Polymorphisms in tumor necrosis factor and other cytokines as risks for infectious diseases and the septic syndrome. Curr Infect Dis Rep 2001; 3:427-439
67. Tracey KJ, Fong Y, Hesse DG, et al: Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330:662-664
68. Jacob CO, Fronek Z, Lewis GD, et al: Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: Relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci U S A 1990; 87:1233-1237
69. Wilson AG, di Giovine FS, Blakemore AI, et al: Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1992; 1:353
70. Louis E, Franchimont D, Piron A, et al: Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998; 113:401-406
71. Stuber F, Udalova IA, Book M, et al: -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J Inflamm 1996; 46:42-50
72. Tang GJ, Huang SL, Yien HW, et al: Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Care Med 2000; 28:2733-2736
73. Mira JP, Cariou A, Grall F, et al: Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: A multicenter study. JAMA 1999; 282:561-568
74. Waterer GW, Quasney MW, Cantor RM, et al: Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 2001; 163: 1599-1604
75. Messer G, Spengler U, Jung MC, et al: Polymorphic structure of the tumor necrosis factor (TNF) locus: An NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 1991; 173:209-219
76. Pociot F, Briant L, Jongeneel CV, et al: Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: A possible link to insulin-dependent diabetes mellitus. Eur J Immunol 1993; 23: 224-231
77. Stuber F, Petersen M, Bokelmann F, et al: A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 1996; 24:381-384
78. Majetschak M, Flohe S, Obertacke U, et al: Relation of a TNF gene polymorphism to severe sepsis in trauma patients. Ann Surg 1999; 230:207-214
79. Schroder J, Kahlke V, Book M, et al: Gender differences in sepsis: Genetically determined? Shock 2000; 14:307-313
80. Arend WP, Malyak M, Guthridge CJ, et al: Interleukin-1 receptor antagonist: Role in biology. Annu Rev Immunol 1998; 16:27-55
81. Tarlow JK, Blakemore AI, Lennard A, et al: Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993; 91:403-404
82. Blakemore AI, Tarlow JK, Cork MJ, et al: Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 1994; 37:1380-1385
83. Blakemore AI, Cox A, Gonzalez AM, et al: Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. Hum Genet 1996; 97: 369-374
84. Mansfield JC, Holden H, Tarlow JK, et al: Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994; 106:637-642
85. Danis VA, Millington M, Huang Q, et al: Lack of association between an interleukin-1 receptor antagonist gene polymorphism and systemic lupus erythematosus. Dis Markers 1995; 12:135-139
86. Hurme M, Santtila S: IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 1998; 28: 2598-2602
87. Danis VA, Millington M, Hyland VJ, et al: Cytokine production by normal human monocytes: Inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995; 99:303-310
88. Pociot F, Molvig J, Wogensen L, et al: A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992; 22:396-402
89. di Giovine FS, Takhsh E, Blakemore AI, et al: Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta). Hum Mol Genet 1992; 1:450
90. Bailly S, di Giovine FS, Blakemore AI, et al: Genetic polymorphism of human interleukin-1 alpha. Eur J Immunol 1993; 23: 1240-1245
91. Fang XM, Schroder S, Hoeft A, et al: Comparison of two polymorphisms of the interleukin-1 gene family: Interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 1999; 27:1330-1334
92. Ma P, Chen D, Pan J, et al: Genomic polymorphism within interleukin-1 family cytokines influences the outcome of septic patients. Crit Care Med 2002; 30:1046-1050
93. Arnalich F, Lopez-Maderuelo D, Codoceo R, et al: Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis. Clin Exp Immunol 2002; 127:331-336
94. Borden EC, Chin P: Interleukin-6: A cytokine with potential diagnostic and therapeutic roles. J Lab Clin Med 1994; 123: 824-829
95. Fisher CJ Jr, Opal SM, Dhainaut JF, et al: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med 1993; 21:318-327
96. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119:771-778
97. Starnes HF Jr, Pearce MK, Tewari A, et al: Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice. J Immunol 1990; 145: 4185-4191
98. Fishman D, Faulds G, Jeffery R, et al: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102:1369-1376
99. Schluter B, Raufhake C, Erren M, et al: Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med 2002; 30: 32-37
100. Heesen M, Obertacke U, Schade FU, et al: The interleukin-6 G(-174)C polymorphism and the ex vivo interleukin-6 response to endotoxin in severely injured blunt trauma patients. Eur Cytokine Netw 2002; 13: 72-77
101. Terry CF, Loukaci V, Green FR: Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000; 275:18138-18144
102. Boehm U, Klamp T, Groot M, et al: Cellular responses to interferon-gamma. Annu Rev Immunol 1997; 15:749-795
103. Cheadle WG, Hershman MJ, Wellhausen SR, et al: HLA-DR antigen expression on peripheral blood monocytes correlates with surgical infection. Am J Surg 1991; 161: 639-645
104. Mock CN, Dries DJ, Jurkovich GJ, et al: Assessment of two clinical trials: Interferon-gamma therapy in severe injury. Shock 1996; 5:235-240
105. Stassen NA, Leslie-Norfleet LA, Robertson AM, et al: Interferon-gamma gene polymorphisms and the development of sepsis in patients with trauma. Surgery 2002; 132: 289-292
106. Davis EG, Eichenberger MR, Grant BS, et al: Microsatellite marker of interferon-gamma receptor 1 gene correlates with infection following major trauma. Surgery 2000; 128:301-305
107. Aird WC: Vascular bed-specific hemostasis: Role of endothelium in sepsis pathogenesis. Crit Care Med 2001; 29(7 Suppl):S28-S35
108. Westendorp RG, Reitsma PH, Bertina RM: Inherited prethrombotic disorders and infectious purpura. Thromb Haemost 1996; 75:899-901
109. Paramo JA, Perez JL, Serrano M, et al: Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor alpha in patients with sepsis. Thromb Haemost 1990; 64:3-6
110. Brandtzaeg P, Joo GB, Brusletto B, et al: Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 1990; 57:271-278
111. Eriksson P, Kallin B, van 't Hooft FM, et al: Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995; 92: 1851-1855
112. Hermans PW, Hibberd ML, Booy R, et al: 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999; 354:556-560
113. Westendorp RG, Hottenga JJ, Slagboom PE: Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999; 354:561-563
114. Menges T, Hermans PW, Little SG, et al: Plasminogen-activator-inhibitor- 1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet 2001; 357: 1096-1097
115. Igic R, Behnia R: Properties and distribution of angiotensin I converting enzyme. Curr Pharm Des 2003; 9:697-706
116. Cambien F, Alhenc-Gelas F, Herbeth B, et al: Familial resemblance of plasma angiotensin-converting enzyme level: The Nancy study. Am J Hum Genet 1988; 43:774-780
117. Rigat B, Hubert C, Alhenc-Gelas F, et al: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346
118. Tiret L, Rigat B, Visvikis S, et al: Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992; 51:197-205
119. Costerousse O, Allegrini J, Lopez M, et al: Angiotensin I-converting enzyme in human circulating mononuclear cells: Genetic polymorphism of expression in T-lymphocytes. Biochem J 1993; 290:33-40
120. Butler R: The DD-ACE genotype and cardiovascular disease. Pharmacogenomics 2000; 1:153-167
121. Kunz R, Bork JP, Fritsche L, et al: Association between the angiotensin-converting enzyme-insertion/deletion polymorphism and diabetic nephropathy: A methodologic appraisal and systematic review. J Am Soc Nephrol 1998; 9:1653-1663
122. Furuya K, Yamaguchi E, Itoh A, et al: Deletion polymorphism in the angiotensin I converting enzyme (ACE) gene as a genetic risk factor for sarcoidosis. Thorax 1996; 51: 777-780
123. Tomita H, Ina Y, Sugiura Y, et al: Polymorphism in the angiotensin-converting enzyme (ACE) gene and sarcoidosis. Am J Respir Crit Care Med 1997; 156:255-259
124. Benessiano J, Crestani B, Mestari F, et al: High frequency of a deletion polymorphism of the angiotensin-converting enzyme gene in asthma. J Allergy Clin Immunol 1997; 99:53-57
125. Harding D, Baines PB, Brull D, et al: Severity of meningococcal disease in children and the angiotensin-converting enzyme insertion/deletion polymorphism. Am J Respir Crit Care Med 2002; 165:1103-1106
126. Marshall RP, Webb S, Bellingan GJ, et al: Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med 2002; 166:646-650
127. Weiss YG, Maloyan A, Tazelaar J, et al: Adenoviral transfer of HSP-70 into pulmonary epithelium ameliorates experimental acute respiratory distress syndrome. J Clin Invest 2002; 110:801-806
128. Schroeder S, Reck M, Hoeft A, et al: Analysis of two human leukocyte antigen-linked polymorphic heat shock protein 70 genes in patients with severe sepsis. Crit Care Med 1999; 27:1265-1270
129. Matthay MA, Zimmerman GA, Esmon C, et al: Future research directions in acute lung injury: Summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med 2003; 167:1027-1035